Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 11/2026 March 15, 2026
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026

Blocking Ant2 Supercharges the Immune System Against Cancer
/in Immunotherapy, Preclinical Research/by MaxPAM50 Subtyping Identifies Patients With Prostate Cancer Most Likely to Benefit From Apalutamide
/in Clinical Trial, Non-Metastatic, Phase 2/by MaxPH1: A Novel Molecule for Advanced Prostate Cancer
/in Antibody-Drug Conjugate, Preclinical Research/by MaxAZD6621: A T-Cell Therapy Targets Hidden Prostate Cancer Driver
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2: Tulmimetostat + ARPI Combo for mHSPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxCancer’s Hidden Brake: How a Hormone Shields Tumors from Immune Attack
/in Immunotherapy, Preclinical Research/by MaxAZD0516: Phase 1 Trial for This STEAP2 ADC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2 Trial for Sacituzumab Tirumotecan and Tagitanlimab Combo
/in Clinical Trial, Metastatic, Phase 2/by Max